Patisiran, an RNAi Therapeutic for the Treatment of Hereditary Transthyretin-Mediated Amyloidosis

Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells

Elbashir, S. M., Harborth, J., Lendeckel, W., Yalcin, A., Weber, K., & Tuschl, T. (2001) · Nature · doi:10.1038/35078107 · Cited by 9,456

RNA interference

Hannon, G. J. (2002) · Nature · doi:10.1038/418244a · Cited by 3,651

Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis

Adams, D., Gonzalez-Duarte, A., O’Riordan, W. D., Yang, C.-C., Ueda, M., Kristen, A. V., Tournev, I., Schmidt, H. H., Coelho, T., Berk, J. L., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1716153 · Cited by 3,047

Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy

Maurer, M. S., Schwartz, J. H., Gundapaneni, B., Elliott, P. M., Merlini, G., Waddington-Cruz, M., Kristen, A. V., Grogan, M., Witteles, R., Damy, T., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1805689 · Cited by 2,857

Protein Misfolding, Amyloid Formation, and Human Disease: A Summary of Progress Over the Last Decade

Chiti, F., & Dobson, C. M. (2017) · Annual Review of Biochemistry · doi:10.1146/annurev-biochem-061516-045115 · Cited by 2,629

Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis

Benson, M. D., Waddington‐Cruz, M., Berk, J. L., Polydefkis, M. J., Dyck, P. J. B., Wang, A. K., Planté‐Bordeneuve, V., Barroso, F. A., Merlini, G., Obici, L. P., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1716793 · Cited by 1,483

Natural History and Outcome in Systemic AA Amyloidosis

Lachmann, H. J., Goodman, H. J. B., Gilbertson, J. A., Gallimore, J. R., Sabin, C. A., Gillmore, J. D., & Hawkins, P. N. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa070265 · Cited by 1,025

New Criteria for Response to Treatment in Immunoglobulin Light Chain Amyloidosis Based on Free Light Chain Measurement and Cardiac Biomarkers: Impact on Survival Outcomes

Palladini, G. O., Dispenzieri, A. A., Gertz, M. A., Kumar, S. K., Wechalekar, A. D., Hawkins, P. N., Schönland, S. O., Hegenbart, U., Comenzo, R. L., Kastritis, E., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.37.7614 · Cited by 978

Safety and efficacy of RNAi therapy for transthyretin amyloidosis

Coelho, T., Adams, D., Silva, A., Lozeron, P., Hawkins, P. N., Mant, T., Perez, J., Chiesa, J., Warrington, S., Tranter, E., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1208760 · Cited by 971

Tafamidis for transthyretin familial amyloid polyneuropathy

Coelho, T., Maia, L. F., SILVA, A. C. F. D., Waddington‐Cruz, M., Planté‐Bordeneuve, V., Lozeron, P., Suhr, O. B., Campistol, J. M., Conceição, I. M., Schmidt, H., et al. (2012) · Neurology · doi:10.1212/wnl.0b013e3182661eb1 · Cited by 812

Repurposing Diflunisal for Familial Amyloid Polyneuropathy

Berk, J. L., Suhr, O. B., Obici, L. P., Sekijima, Y., Zeldenrust, S. R., Yamashita, T., Heneghan, M. A., Gorevic, P. D., Litchy, W. J., Wiesman, J. F., et al. (2013) · JAMA · doi:10.1001/jama.2013.283815 · Cited by 719

Transthyretin (TTR) Cardiac Amyloidosis

Ruberg, F. L., & Berk, J. L. (2012) · Circulation · doi:10.1161/circulationaha.111.078915 · Cited by 710

Association Between Nonsteroidal Anti-inflammatory Drugs and Upper Gastrointestinal Tract Bleeding/Perforation

Hernández–Dı́az, S., & Rodríguez, L. A. G. (2000) · Archives of Internal Medicine · doi:10.1001/archinte.160.14.2093 · Cited by 707

Fibril in senile systemic amyloidosis is derived from normal transthyretin.

Westermark, P., Sletten, K., Johansson, B., & Cornwell, G. G. (1990) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.87.7.2843 · Cited by 698

Guideline of transthyretin-related hereditary amyloidosis for clinicians

Ando, Y., Coelho, T., Berk, J., Cruz, M., Ericzon, B., Ikeda, S., Lewis, W., Obici, L., Planté-Bordeneuve, V., Rapezzi, C., et al. (2013) · Orphanet Journal of Rare Diseases · doi:10.1186/1750-1172-8-31 · Cited by 682

Amyloid fibril proteins and amyloidosis: chemical identification and clinical classification International Society of Amyloidosis 2016 Nomenclature Guidelines

Sipe, J. D., Benson, M. D., Buxbaum, J. N., Ikeda, S.-I., Merlini, G., Saraiva, M. J., & Westermark, P. (2016) · Amyloid · doi:10.1080/13506129.2016.1257986 · Cited by 603

Lipid nanoparticles enabling gene therapies: from concepts to clinical utility

Kulkarni, J. A., Cullis, P. R., & van der Meel, R. (2018) · Nucleic Acid Therapeutics · doi:10.1089/nat.2018.0721 · Cited by 592

Amyloid load and clinical outcome in AA amyloidosis in relation to circulating concentration of serum amyloid A protein

Gillmore, J. D., Lovat, L. B., Persey, M. R., Pepys, M. B., & Hawkins, P. N. (2001) · The Lancet · doi:10.1016/s0140-6736(00)05252-1 · Cited by 586

Genotype and Phenotype of Transthyretin Cardiac Amyloidosis

Maurer, M. S., Hanna, M. A., Grogan, M. A., Dispenzieri, A. A., Witteles, R. M., Drachman, B. M., Judge, D. P., Lenihan, D. J., Gottlieb, S. S., Shah, S. J., et al. (2016) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2016.03.596 · Cited by 536

Amyloid fibril protein in familial amyloidotic polyneuropathy, Portuguese type. Definition of molecular abnormality in transthyretin (prealbumin).

Saraiva, M. J., Birken, S., Costa, P., & Goodman, D. S. (1984) · Journal of Clinical Investigation · doi:10.1172/jci111390 · Cited by 437

Outcome in systemic AL amyloidosis in relation to changes in concentration of circulating free immunoglobulin light chains following chemotherapy

Lachmann, H. J., Gallimore, J. R., Gillmore, J. D., Carr-Smith, H. D., Bradwell, A. R., Pepys, M. B., & Hawkins, P. N. (2003) · British Journal of Haematology · doi:10.1046/j.1365-2141.2003.04433.x · Cited by 431

Transthyretin-Related Familial Amyloidotic Polyneuropathy

Ando, Y., Nakamura, M., & Araki, S. (2005) · Archives of Neurology · doi:10.1001/archneur.62.7.1057 · Cited by 416

Structure of a complex of two plasma proteins: transthyretin and retinol-binding protein

Monaco, H. L., Rizzi, M., & Coda, A. (1995) · Science · doi:10.1126/science.7754382 · Cited by 413

Amyloid and Amyloidosis

Glynn, L. E. (1981) · Immunology · Cited by 412

Biochemical effect of liver transplantation in two Swedish patients with familial amyloidotic polyneuropathy (FAP‐met30)

Holmgren, G., Steen, L., Ekstedt, J., Groth, C., Ericzon, B. ‐., Eriksson, S., Andersen, O., Karlberg, I. H., Nordén, G., Nakazato, M., et al. (1991) · Clinical Genetics · doi:10.1111/j.1399-0004.1991.tb03085.x · Cited by 395

Left Ventricular Structure and Function in Transthyretin-Related Versus Light-Chain Cardiac Amyloidosis

Quarta, C. C., Solomon, S. D., Uraizee, I., Kruger, J., Longhi, S., Ferlito, M., Gagliardi, C., Milandri, A., Rapezzi, C., & Falk, R. H. (2014) · Circulation · doi:10.1161/circulationaha.113.006242 · Cited by 345

THAOS – The Transthyretin Amyloidosis Outcomes Survey: initial report on clinical manifestations in patients with hereditary and wild-type transthyretin amyloidosis

Coelho, T., Maurer, M. S., & Suhr, O. B. (2012) · Current Medical Research and Opinion · doi:10.1185/03007995.2012.754348 · Cited by 345

Disease profile and differential diagnosis of hereditary transthyretin-related amyloidosis with exclusively cardiac phenotype: an Italian perspective

Rapezzi, C., Quarta, C. C., Obici, L. P., Perfetto, F., Longhi, S., Salvi, F., Biagini, E., Lorenzini, M., Grigioni, F., Leone, O., et al. (2012) · European Heart Journal · doi:10.1093/eurheartj/ehs123 · Cited by 330

Efficacy and safety of patisiran for familial amyloidotic polyneuropathy: a phase II multi-dose study

Suhr, O. B., Coelho, T., Buades, J., Pouget, J., Conceicao, I., Berk, J., Schmidt, H., Waddington-Cruz, M., Campistol, J. M., Bettencourt, B. R., et al. (2015) · Orphanet Journal of Rare Diseases · doi:10.1186/s13023-015-0326-6 · Cited by 321

Liver Transplantation for Hereditary Transthyretin Amyloidosis

Ericzon, B., Wilczek, H., Larsson, M., Wijayatunga, P. D. C., Stangou, A. J., Peña, J., Furtado, E., Barroso, E., Daniel, J., Samuel, D., et al. (2015) · Transplantation · doi:10.1097/tp.0000000000000574 · Cited by 311

Online Registry for Mutations in Hereditary Amyloidosis Including Nomenclature Recommendations

Rowczenio, D. M., Noor, I., Gillmore, J. D., Lachmann, H. J., Whelan, C. J., Hawkins, P. N., Obici, L. P., Westermark, P., Grateau, G., & Wechalekar, A. D. (2014) · Human Mutation · doi:10.1002/humu.22619 · Cited by 307

“Red‐flag” symptom clusters in transthyretin familial amyloid polyneuropathy

Conceição, I. M., González‐Duarte, A., Obici, L. P., Schmidt, H., Simoneau, D., Ong, M., & Amass, L. (2015) · Journal of the Peripheral Nervous System · doi:10.1111/jns.12153 · Cited by 298

Ten years of international experience with liver transplantation for familial amyloidotic polyneuropathy: results from the familial amyloidotic polyneuropathy world transplant registry

Herlenius, G., Wilczek, H., Larsson, M., & Ericzon, B. (2004) · Transplantation · doi:10.1097/01.tp.0000092307.98347.cb · Cited by 274

Pharmacokinetics and therapeutics of sterically stabilized liposomes in mice bearing C-26 colon carcinoma.

Huang, S. K., Mayhew, E. G., Gilani, S., Lasiç, D. D., Martin, F. J., & Papahadjopoulos, D. (1992) · PubMed · Cited by 274

Orally administered diflunisal stabilizes transthyretin against dissociation required for amyloidogenesis

Sekijima, Y., Dendle, M. A., & Kelly, J. W. (2006) · Amyloid · doi:10.1080/13506120600960882 · Cited by 269

Prospective evaluation of the morbidity and mortality of wild-type and V122I mutant transthyretin amyloid cardiomyopathy: The Transthyretin Amyloidosis Cardiac Study (TRACS)

Ruberg, F. L., Maurer, M. S., Judge, D. P., Zeldenrust, S. R., Skinner, M. M., Kim, A. Y., Falk, R. H., Cheung, K. N., Patel, A. R., Pano, A., et al. (2012) · American Heart Journal · doi:10.1016/j.ahj.2012.04.015 · Cited by 263

Natural history and therapy of TTR-cardiac amyloidosis: emerging disease-modifying therapies from organ transplantation to stabilizer and silencer drugs

Castaño, A., Drachman, B. M., Judge, D. P., & Maurer, M. S. (2014) · Heart Failure Reviews · doi:10.1007/s10741-014-9462-7 · Cited by 258

Demonstration of transthyretin mRNA in the brain and other extrahepatic tissues in the rat.

Soprano, D. R., Herbert, J., Soprano, K. J., Schon, E. A., & Goodman, D. S. (1985) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)39100-7 · Cited by 254

The course and prognostic factors of familial amyloid polyneuropathy after liver transplantation

Adams, D. (2000) · Brain · doi:10.1093/brain/123.7.1495 · Cited by 253

Evolving landscape in the management of transthyretin amyloidosis

Hawkins, P. N., Ando, Y., Dispenzeri, A., González‐Duarte, A., Adams, D., & Suhr, O. B. (2015) · Annals of Medicine · doi:10.3109/07853890.2015.1068949 · Cited by 248

Diagnostic pitfalls in sporadic transthyretin familial amyloid polyneuropathy (TTR-FAP)

Planté‐Bordeneuve, V., Ferreira, A. C., Lalu, T., Zaros, C., Lacroix, C., Adams, D., & Saïd, G. (2007) · Neurology · doi:10.1212/01.wnl.0000267338.45673.f4 · Cited by 243

First European consensus for diagnosis, management, and treatment of transthyretin familial amyloid polyneuropathy

Adams, D., Suhr, O. B., Hund, E., Obici, L. P., Tournev, I., Campistol, J. M., Slama, M., Hazenberg, B. P. C., & Coelho, T. (2016) · Current Opinion in Neurology · doi:10.1097/wco.0000000000000289 · Cited by 241

Genetic epidemiology of familial amyloidotic polyneuropathy (FAP)‐type I in Póvoa do Varzim and Vila do Conde (north of Portugal)

Sousa, A., Coelho, T., Barros, J., & Sequeiros, J. (1995) · American Journal of Medical Genetics · doi:10.1002/ajmg.1320600606 · Cited by 236

Sixty years of transthyretin familial amyloid polyneuropathy (TTR-FAP) in Europe

Parman, Y., Adams, D., Obici, L. P., Galán, L., Guergueltcheva, V., Suhr, O. B., & Coelho, T. (2016) · Current Opinion in Neurology · doi:10.1097/wco.0000000000000288 · Cited by 234

Cardiac amyloidosis: Updates in diagnosis and management

Mohty, D., Damy, T., Cosnay, P., Echahidi, N., Casset-Senon, D., Virot, P., & Jaccard, A. (2013) · Archives of cardiovascular diseases · doi:10.1016/j.acvd.2013.06.051 · Cited by 228

Natural history of transthyretin Val30Met familial amyloid polyneuropathy: analysis of late-onset cases from non-endemic areas

Koike, H., Tanaka, F., Hashimoto, R., Tomita, M., Kawagashira, Y., Iijima, M., Fujitake, J., Kawanami, T., Kato, T., Yamamoto, M., et al. (2012) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2011-301299 · Cited by 210

Transthyretin mutations in hyperthyroxinemia and amyloid diseases

Saraiva, M. J. (2001) · Human Mutation · doi:10.1002/humu.1132 · Cited by 206

Amyloid fibril formation and protein misassembly: a structural quest for insights into amyloid and prion diseases

Kelly, J. W. (1997) · Structure · doi:10.1016/s0969-2126(97)00215-3 · Cited by 205

Cardiac phenotype and clinical outcome of familial amyloid polyneuropathy associated with transthyretin alanine 60 variant

Sattianayagam, P. T., Hahn, A. F., Whelan, C. J., Gibbs, S. D., Pinney, J. H., Stangou, A. J., Rowczenio, D. M., Pflugfelder, P. W., Fox, Z. V., Lachmann, H. J., et al. (2011) · European Heart Journal · doi:10.1093/eurheartj/ehr383 · Cited by 195

Transthyretin: A multifaceted protein

Vieira, M., & Saraiva, M. J. (2014) · BioMolecular Concepts · doi:10.1515/bmc-2013-0038 · Cited by 185

Synergy of combined Doxycycline/TUDCA treatment in lowering Transthyretin deposition and associated biomarkers: studies in FAP mouse models

Cardoso, I., Martins, D. F., Ribeiro, T., Merlini, G., & Saraiva, M. J. (2010) · Journal of Translational Medicine · doi:10.1186/1479-5876-8-74 · Cited by 184

Trial design and rationale for APOLLO, a Phase 3, placebo-controlled study of patisiran in patients with hereditary ATTR amyloidosis with polyneuropathy

Adams, D., Suhr, O. B., Dyck, P. J. B., Litchy, W. J., Leahy, R. G., Chen, J., Gollob, J., & Coelho, T. (2017) · BMC Neurology · doi:10.1186/s12883-017-0948-5 · Cited by 181

Progression of transthyretin amyloid neuropathy after liver transplantation

Liepnieks, J. J., Zhang, L. Q., & Benson, M. D. (2010) · Neurology · doi:10.1212/wnl.0b013e3181ea15d4 · Cited by 158

Diflunisal for ATTR Cardiac Amyloidosis

Castaño, A., Helmke, S. T., Alvarez, J., Delisle, S., & Maurer, M. S. (2012) · Congestive Heart Failure · doi:10.1111/j.1751-7133.2012.00303.x · Cited by 156

Rapid progression of familial amyloidotic polyneuropathy

Adams, D., Coelho, T., Obici, L. P., Merlini, G., Mincheva, Z., Suanprasert, N., Bettencourt, B. R., Gollob, J., Gandhi, P. J., Litchy, W. J., et al. (2015) · Neurology · doi:10.1212/wnl.0000000000001870 · Cited by 155

Forty years of experience with type I amyloid neuropathy. Review of 483 cases

Coutinho, P., da Silva, A. L., Lopes, J. M., Resende, P.-E. A., Silva, A. M. D., Resende, L. A. L., Silva, A. M.-D., Filho, J. D. L., & Barbosa, A. (1980) · Cited by 149

Cardiac transthyretin amyloidosis

Dungu, J. N., Anderson, L. J., Whelan, C. J., & Hawkins, P. N. (2012) · Heart · doi:10.1136/heartjnl-2012-301924 · Cited by 140

Antisense Strategies

Crooke, S. T. (2004) · Current Molecular Medicine · doi:10.2174/1566524043360375 · Cited by 139

Amyloid Neuropathies

Shin, S. C., & Robinson‐Papp, J. (2012) · Mount Sinai Journal of Medicine A Journal of Translational and Personalized Medicine · doi:10.1002/msj.21352 · Cited by 138

Systemic senile amyloidosis. Identification of a new prealbumin (transthyretin) variant in cardiac tissue: immunologic and biochemical similarity to one form of familial amyloidotic polyneuropathy.

Gorevic, P. D., Prelli, F. C., Wright, J. R., Pras, M., & Frangione, B. (1989) · Journal of Clinical Investigation · doi:10.1172/jci113966 · Cited by 133

One mutation, two distinct disease variants: unravelling the impact of transthyretin amyloid fibril composition

Suhr, O. B., Lundgren, E., & Westermark, P. (2017) · Journal of Internal Medicine · doi:10.1111/joim.12585 · Cited by 133

Effect on disability and safety of Tafamidis in late onset of Met30 transthyretin familial amyloid polyneuropathy

Lozeron, P., Théaudin, M., Mincheva, Z., Ducot, B., Lacroix, C., Adams, D., & French Network for FAP (CORNAMYL) (2013) · European Journal of Neurology · doi:10.1111/ene.12225 · Cited by 129

Clinical variability in type I familial amyloid polyneuropathy (Val30Met): Comparison between late‐ and early‐onset cases in Portugal

Conceição, I. M., & de Carvalho, M. A. (2006) · Muscle & Nerve · doi:10.1002/mus.20644 · Cited by 128

Norfolk QOL‐DN : validation of a patient reported outcome measure in transthyretin familial amyloid polyneuropathy

Vinik, E. J., Vinik, A. I., Paulson, J. F., Merkies, I. S. J., Packman, J., Grogan, D. R., & Coelho, T. (2014) · Journal of the Peripheral Nervous System · doi:10.1111/jns5.12059 · Cited by 114

THAOS: Gastrointestinal manifestations of transthyretin amyloidosis - common complications of a rare disease

Wixner, J., Mundayat, R., Karayal, O. N., Anan, I., Karling, P., Suhr, O. B., & on behalf of the THAOS investigators (2014) · Orphanet Journal of Rare Diseases · doi:10.1186/1750-1172-9-61 · Cited by 112

Familial Amyloidosis: A Study of 52 North American-Born Patients Examined During a 30-Year Period

Gertz, M. A., Kyle, R. A., & Thibodeau, S. N. (1992) · Mayo Clinic Proceedings · doi:10.1016/s0025-6196(12)60388-7 · Cited by 112

Plasminogen activation triggers transthyretin amyloidogenesis in vitro

Mangione, P. P., Verona, G., Corazza, A., Marcoux, J., Canetti, D., Giorgetti, S., Raimondi, S., Stoppini, M., Esposito, M., Relini, A., et al. (2018) · Journal of Biological Chemistry · doi:10.1074/jbc.ra118.003990 · Cited by 111

Hereditary ATTR amyloidosis: a single-institution experience with 266 patients

Swiecicki, P. L., Zhen, D. B., Mauermann, M. L., Kyle, R. A., Zeldenrust, S. R., Grogan, M. A., Dispenzieri, A. A., & Gertz, M. A. (2015) · Amyloid · doi:10.3109/13506129.2015.1019610 · Cited by 110

Long-term treatment of transthyretin familial amyloid polyneuropathy with tafamidis: a clinical and neurophysiological study

Planté‐Bordeneuve, V., Gorram, F., Salhi, H., Nordine, T., Ayache, S. S., Corvoisier, P. L., Azoulay, D., Féray, C., Damy, T., & Lefaucheur, J. (2016) · Journal of Neurology · doi:10.1007/s00415-016-8337-3 · Cited by 108

Cerebral amyloid angiopathy in posttransplant patients with hereditary ATTR amyloidosis

Sekijima, Y., Yazaki, M., Oguchi, K., Ezawa, N., Yoshinaga, T., Yamada, M., Yahikozawa, H., Watanabe, M., Kametani, F., & Ikeda, S. (2016) · Neurology · doi:10.1212/wnl.0000000000003001 · Cited by 107

Recent advances in the treatment of familial amyloid polyneuropathy

Adams, D. (2012) · Therapeutic Advances in Neurological Disorders · doi:10.1177/1756285612470192 · Cited by 100

Monitoring effectiveness and safety of Tafamidis in transthyretin amyloidosis in Italy: a longitudinal multicenter study in a non-endemic area

Cortese, A., Vita, G., Luigetti, M., Russo, M., Bisogni, G., Sabatelli, M., Manganelli, F., Santoro, L., Cavallaro, T., Fabrizi, G. M., et al. (2016) · Journal of Neurology · doi:10.1007/s00415-016-8064-9 · Cited by 98

Peripheral nerve involvement in primary systemic AL amyloidosis: a clinical and electrophysiological study

Matsuda, M., Gono, T., Morita, H., Katoh, N., Kodaira, M., & Ikeda, S. (2010) · European Journal of Neurology · doi:10.1111/j.1468-1331.2010.03215.x · Cited by 97

The use of the New york heart association's classification of cardiovascular disease as part of the patient's complete problem list

Hurst, J. W., Morris, D. C., & Alexander, R. W. (1999) · Clinical Cardiology · doi:10.1002/clc.4960220604 · Cited by 96

[Cardiac Transthyretin Amyloidosis].

Manganiello, C. F. (2020) · PubMed · Cited by 96

Novel conformation-specific monoclonal antibodies against amyloidogenic forms of transthyretin

Higaki, J. N., Chakrabartty, A., Galant, N. J., Hadley, K. C., Hammerson, B., Nijjar, T., Torres, R., Tapia, J. R., Salmans, J., Barbour, R., et al. (2016) · Amyloid · doi:10.3109/13506129.2016.1148025 · Cited by 92

Tafamidis

Saïd, G., Grippon, S., & Kirkpatrick, P. N. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3675 · Cited by 86

Systemic amyloidosis: a challenge for the rheumatologist

Perfetto, F., Pignone, A. M., Livi, R., Tempestini, A., Bergesio, F., & Matucci‐Cerinic, M. (2010) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2010.84 · Cited by 86

Survival After Transplantation in Patients With Mutations Other Than Val30Met

Suhr, O. B., Larsson, M., Ericzon, B., & Wilczek, H. (2015) · Transplantation · doi:10.1097/tp.0000000000001021 · Cited by 76

FAP Neuropathy and Emerging Treatments

Adams, D., Théaudin, M., Cauquil, C., Algalarrondo, V., & Slama, M. (2014) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-013-0435-3 · Cited by 71

Impact of Liver Transplantation on Transthyretin-Related Ocular Amyloidosis in Japanese Patients

Hara, R. (2010) · Archives of Ophthalmology · doi:10.1001/archophthalmol.2009.390 · Cited by 71

Aboard transthyretin: From transport to cleavage

Liz, M. A., Mar, F. M., Franquinho, F., & Sousa, M. M. (2010) · IUBMB Life · doi:10.1002/iub.340 · Cited by 68

Marked Regression of Abdominal Fat Amyloid in Patients With Familial Amyloid Polyneuropathy During Long-Term Follow-Up After Liver Transplantation

Tsuchiya, A., Yazaki, M., Kametani, F., Takei, Y., & Ikeda, S. (2008) · Liver Transplantation · doi:10.1002/lt.21395 · Cited by 67

Novel Drugs Targeting Transthyretin Amyloidosis

Hanna, M. (2014) · Current Heart Failure Reports · doi:10.1007/s11897-013-0182-4 · Cited by 65

Cardiac Findings and Events Observed in an Open-Label Clinical Trial of Tafamidis in Patients with non-Val30Met and non-Val122Ile Hereditary Transthyretin Amyloidosis

Damy, T., Judge, D. P., Kristen, A. V., Berthet, K., Li, H., & Aarts, J. M. (2015) · Journal of Cardiovascular Translational Research · doi:10.1007/s12265-015-9613-9 · Cited by 64

De novo malignancies following liver transplantation: a case–control study with long‐term follow‐up

Yao, F. Y., Gautam, M., Palese, C., Rebres, R., Terrault, N. A., Roberts, J. P., & Peters, M. G. (2006) · Clinical Transplantation · doi:10.1111/j.1399-0012.2006.00527.x · Cited by 60

Effects of tafamidis treatment on transthyretin (TTR) stabilization, efficacy, and safety in Japanese patients with familial amyloid polyneuropathy (TTR-FAP) with Val30Met and non-Val30Met: A phase III, open-label study

Ando, Y., Sekijima, Y., Obayashi, K., Yamashita, T., Ueda, M., Misumi, Y., Morita, H., Machii, K., Ohta, M., Takata, A., et al. (2016) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2016.01.046 · Cited by 57

Pathogenesis of transthyretin amyloidosis

Benson, M. D. (2012) · Amyloid · doi:10.3109/13506129.2012.668501 · Cited by 40

Substoichiometric inhibition of transthyretin misfolding by immune-targeting sparsely populated misfolding intermediates: a potential diagnostic and therapeutic for TTR amyloidoses

Galant, N. J., Bugyei‐Twum, A., Rakhit, R., Walsh, P. J., Sharpe, S. J., Arslan, P. E., Westermark, P., Higaki, J. N., Torres, R., Tapia, J. R., et al. (2016) · Scientific Reports · doi:10.1038/srep25080 · Cited by 37

Assessment of nonsteroidal anti-inflammatory drug-induced cardiotoxicity

Singh, B. K., Haque, S. E., & Pillai, K. K. (2013) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2014.856881 · Cited by 34

Unusual duplication mutation in a surface loop of human transthyretin leads to an aggressive drug-resistant amyloid disease

Klimtchuk, E. S., Prokaeva, T. B., Frame, N. M., Abdullahi, H., Spencer, B., Dasari, S., Cui, H., Berk, J. L., Kurtin, P. J., Connors, L. H., et al. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1802977115 · Cited by 34

New spastic paraplegia phenotype associated to mutation of NFU1

Tonduti, D., Dorboz, I., Imbard, A., Slama, A., Boutron, A., Pichard, S., Elmaleh, M., Vallée, L., Benoist, J., de Baulny, H. O., et al. (2015) · Orphanet Journal of Rare Diseases · doi:10.1186/s13023-015-0237-6 · Cited by 33

Quality of life in patients with familial amyloidotic polyneuropathy long-term after liver transplantation

Drent, G., Graveland, C. W., Hazenberg, B. P. C., & Haagsma, E. B. (2009) · Amyloid · doi:10.1080/13506120903090726 · Cited by 29

Familial amyloidotic polyneuropathy: long-term follow-up of abdominal fat tissue aspirate in patients with and without liver transplantation

Haagsma, E. B., Gameren, I. I. V., Bijzet, J., Posthumus, M. D., & Hazenberg, B. P. C. (2007) · Amyloid · doi:10.1080/13506120701461368 · Cited by 24

Newer Therapies for Amyloid Cardiomyopathy

Chakraborty, R., Muchtar, E., & Gertz, M. A. (2016) · Current Heart Failure Reports · doi:10.1007/s11897-016-0300-1 · Cited by 16

Cardiovascular Risk of NSAIDs: Time to Translate Knowledge into Practice

Reddy, K. S., & Roy, A. (2013) · PLoS Medicine · doi:10.1371/journal.pmed.1001389 · Cited by 16

Phase 1 study of ALN-TTRsc02, a subcutaneously administered investigational RNAi therapeutic for the treatment of transthyretin-mediated amyloidosis

Adams, D. H., & Karsten, V. (2019) · Revue Neurologique · doi:10.1016/j.neurol.2019.01.339 · Cited by 15

Phase 2 Open-Label Extension (OLE) Study of Patisiran, an Investigational RNA interference (RNAi) Therapeutic for the Treatment of Hereditary ATTR Amyloidosis with Polyneuropathy (S27.004)

Adams, D., Coelho, T., Conceição, I. M., Waddington‐Cruz, M., Schmidt, H., Buades, J., Campistol, J. M., Pouget, J., Berk, J. L., Polydefkis, M. J., et al. (2017) · Neurology · doi:10.1212/wnl.88.16_supplement.s27.004 · Cited by 12

Preliminary assessment of neuropathy progression in patients with hereditary ATTR amyloidosis after orthotopic liver transplantation (OLT)

Adams, D., Buades, J., Suhr, O. B., Obici, L. P., & Coelho, T. (2015) · Orphanet Journal of Rare Diseases · doi:10.1186/1750-1172-10-s1-p19 · Cited by 12

Analysis of disease progression in patients with transthyretin cardiac amyloidosis

Gilmore, J. D., Maurer, M. S., Vest, J., Karsten, V., Powell, C., Strahs, A. L., Gollob, J., & Hawkins, P. N. (2015) · Orphanet Journal of Rare Diseases · doi:10.1186/1750-1172-10-s1-o10 · Cited by 4

Phase 2 open-label extension study of patisiran, an investigational siRNA agent for hereditary ATTR amyloidosis with polyneuropathy (hATTR-PN)

Conceição, I. M., Suhr, O. B., Coelho, T., Waddington‐Cruz, M., Schmidt, H., Buades, J., Campistol, J. M., Pouget, J., Berk, J. L., & Adams, D. (2016) · Neuromuscular Disorders · doi:10.1016/j.nmd.2016.06.206 · Cited by 3

Infusion related reactions in patients with hATTR amyloidosis treated with patisiran

Polydefkis, M. J., Adams, D., Coelho, T., Kristen, A. V., González‐Duarte, A., Berk, J. L., Quan, D., Partisano, A. M., Gollob, J., Sweester, M., et al. (2018) · Journal of the Peripheral Nervous System · Cited by 2

Efficiency of siRNA for removal of transthyretin V30M in a TTR leptomeningeal animal model

Gonçalves, P., Martins, S., Costelha, S., & Saraiva, M. J. (2017) · Amyloid · doi:10.1080/13506129.2016.1272452 · Cited by 2

Safety and Efficacy of Long-Term Diflunisal Administration in Familial Amyloid Polyneuropathy (PD1.009)

Sekijima, Y., Tojo, K., Morita, H., Koyama, J., Koike, H., Sobue, G., & Ikeda, S. (2013) · Neurology · doi:10.1212/wnl.80.7_supplement.pd1.009 · Cited by 1

The Potential for microRNA Therapeutics and Clinical Research

Hanna, J., Hossain, G. S., & Kocerha, J. (2019) · Frontiers in Genetics · doi:10.3389/fgene.2019.00478 · Cited by 755

Advances in COVID-19 mRNA vaccine development

Fang, E., Liu, X., Li, M., Zhang, Z., Song, L., Zhu, B., Wu, X., Liu, J., Zhao, D., & Li, Y. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-00950-y · Cited by 601

Lipid Nanoparticles for Drug Delivery

Xu, L., Wang, X., Liu, Y., Yang, G., Falconer, R. J., & Zhao, C. (2021) · Advanced NanoBiomed Research · doi:10.1002/anbr.202100109 · Cited by 588

The Limitless Future of RNA Therapeutics

Damase, T. R., Sukhovershin, R. A., Boada, C., Taraballi, F., Pettigrew, R. I., & Cooke, J. P. (2021) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2021.628137 · Cited by 577

Huntington disease: new insights into molecular pathogenesis and therapeutic opportunities

Tabrizi, S. J., Flower, M. D., Ross, C. A., & Wild, E. J. (2020) · Nature Reviews Neurology · doi:10.1038/s41582-020-0389-4 · Cited by 568

Patisiran for the treatment of hereditary transthyretin-mediated amyloidosis

Yang, J. (2019) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2019.1567326 · Cited by 73

An evaluation of patisiran: a viable treatment option for transthyretin-related hereditary amyloidosis

Milani, P., Mussinelli, R., Perlini, S., Palladini, G. O., & Obici, L. P. (2019) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2019.1671352 · Cited by 11

Long-term safety and efficacy of patisiran for hereditary transthyretin-mediated amyloidosis with polyneuropathy: 12-month results of an open-label extension study

Adams, D., Polydefkis, M., González-Duarte, A., Wixner, J., Kristen, A. V., Schmidt, H. H., Berk, J. L., Losada López, I. A., Dispenzieri, A., Quan, D., et al. (2021) · The Lancet Neurology · doi:10.1016/s1474-4422(20)30368-9 · Cited by 158

Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis

Adams, D., Gonzalez-Duarte, A., O’Riordan, W. D., Yang, C.-C., Ueda, M., Kristen, A. V., Tournev, I., Schmidt, H. H., Coelho, T., Berk, J. L., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1716153 · Cited by 3,047

A Review of Patisiran (ONPATTRO®) for the Treatment of Polyneuropathy in People with Hereditary Transthyretin Amyloidosis

Urits, I., Swanson, D., Swett, M. C., Patel, A., Berardino, K., Amgalan, A., Berger, A. A., Kassem, H., Kaye, A. D., & Viswanath, O. (2020) · Neurology and Therapy · doi:10.1007/s40120-020-00208-1 · Cited by 282